Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 13/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 12/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 12/20 | 0.55 |
| ▸ | PRKDC | P78527 | 12/20 | 0.55 |
| ▸ | ABL1 | P00519 | 11/20 | 0.54 |
| ▸ | SRC | P12931 | 11/20 | 0.54 |
| ▸ | EGFR | P00533 | 10/20 | 0.54 |
| ▸ | HCK | P08631 | 9/20 | 0.54 |
| ▸ | MTOR | P42345 | 9/20 | 0.54 |
| ▸ | EPHB4 | P54760 | 9/20 | 0.54 |
| ▸ | KDR | P35968 | 8/20 | 0.54 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.53 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.53 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.50 |
| ▸ | ABL2 | P42684 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.48 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.48 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655671 | 0.78 | PIK3CD (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL409367 | 0.76 | PIK3CD (0.82) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL23917209 | 0.76 | PIK3CD (0.63) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL23917528 | 0.76 | PIK3CA (0.61) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL21084183 | 0.75 | PIK3CD (0.56) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL129888 | 0.75 | PIK3CD (0.58) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL129486 | 0.75 | PIK3CD (0.73) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL128451 | 0.75 | PIK3CD (0.53) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL16655792 | 0.74 | ATR (0.64) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC | |
| SCHEMBL19414364 | 0.72 | SRC (0.43) | PIK3CDPIK3CAPIK3CBPIK3CGPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-26 | — | — | US | disclosed |
| US-9775841-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2016-11-03 | — | — | US | disclosed |
| US-9421209-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2016-08-23 | — | — | US | disclosed |
| EP-3050876-A2 | KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2016-08-03 | — | — | EP | disclosed |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| US-20150174131-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-9018375-B2 | Substituted chromenes as kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2015-04-28 | — | — | US | disclosed |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2014-03-20 | — | — | US | disclosed |
| US-8642607-B2 | 4H-chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2014-02-04 | — | — | US | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174131-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PIK3CD 70/4885PIK3CA 143/4885PIK3CB 33/4885 |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PIK3CD 47/4885PIK3CA 88/4885PIK3CB 23/4885 |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PIK3CD 47/4885PIK3CA 88/4885PIK3CB 23/4885 |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PIK3CD 47/4885PIK3CA 88/4885PIK3CB 23/4885 |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PIK3CD 70/4885PIK3CA 143/4885PIK3CB 33/4885 |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PIK3CD 70/4885PIK3CA 143/4885PIK3CB 33/4885 |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | PIK3CD 2/4885PIK3CA 6/4885PIK3CB 3/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | PIK3CD 103/4885PIK3CA 144/4885PIK3CB 102/4885 |
| US-20160318890-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PIK3CD 70/4885PIK3CA 143/4885PIK3CB 33/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | PIK3CD 70/4885PIK3CA 143/4885PIK3CB 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.